Belzutifan, the 1st hypoxia-inducible factor (HIF) inhibitor is FDA-approved.  Plus, expanded indication approvals for nivolumab, dostarlimab, lenvatinib/pembrolizumab, & Ivosidenib.  Finally, my Top 5 Rolling Stones Songs (14:30).

Belzutifan, the 1st hypoxia-inducible factor (HIF) inhibitor is FDA-approved.  Plus, expanded indication approvals for nivolumab, dostarlimab, lenvatinib/pembrolizumab, & Ivosidenib.  Finally, my Top 5 Rolling Stones Songs

Hypercalcemia Of Malignancy (in Under 10)

OncoPharm is a podcast dedicated to all things oncology pharmacy.  Most episodes cover updates and recent publications concerning the use of medications in caring for patients we cancer.  Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.